Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | NPY4R | P50391 | 11/20 | 0.39 |
| ▸ | NPY1R | P25929 | 7/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.35 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.35 |
| ▸ | CALCR | P30988 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740225 | 1.00 | NOD1 (0.46) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29613330 | 0.92 | NOD1 (0.45) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29540572 | 0.92 | NPY4R (0.39) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29870738 | 0.91 | NOD1 (0.46) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL5598692 | 0.91 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29697052 | 0.91 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL2490761 | 0.91 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31454130 | 0.91 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29787128 | 0.91 | NOD1 (0.52) | NOD1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30898574 | 0.91 | NPY4R (0.38) | NOD1NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | NOD1 463/4885NPY4R 58/4885NPY1R 121/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | NOD1 463/4885NPY4R 58/4885NPY1R 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.